Relay Therapeutics utilizes its Dynamo platform, which combines experimental and computational techniques, to visualize protein motion in real-time, enabling the identification of allosteric drug targets. The company focuses on developing therapeutic candidates for precision oncology and genetic diseases, targeting previously intractable proteins to create effective treatments.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery methods often struggle to target proteins effectively due to their dynamic nature and complex conformational changes. Many proteins, particularly those involved in cancer and genetic diseases, have been considered "undruggable" because conventional approaches fail to account for protein motion and allosteric regulation. This limitation hinders the development of effective treatments for a wide range of diseases.
Solution
Relay Therapeutics employs its Dynamo platform, a proprietary technology that integrates experimental and computational methods to visualize protein motion in real-time. This approach enables the identification of allosteric binding sites and cryptic pockets that are only accessible in certain protein conformations. By understanding protein dynamics, Relay Therapeutics aims to design therapeutic candidates that selectively modulate protein function, even for targets previously deemed intractable. The company focuses on developing precision medicines for oncology and genetic diseases by targeting specific protein conformations and regulatory mechanisms.
Target Audience
The primary target audience includes patients with cancer and genetic diseases who lack effective treatment options, as well as pharmaceutical companies seeking innovative drug discovery platforms and novel therapeutic candidates.
Features
- Dynamo platform: Integrates experimental biophysics, computational chemistry, and structural biology to visualize protein motion.
- Allosteric drug discovery: Focuses on identifying and targeting allosteric sites to modulate protein function.
- Structure-based design: Utilizes high-resolution protein structures and computational modeling to design selective inhibitors.
- Real-time protein visualization: Enables the observation of conformational changes and dynamic interactions.
- Precision oncology pipeline: Developing targeted therapies for specific cancer subtypes based on protein mutations and dysregulation.
- Genetic disease program: Targeting proteins involved in inherited disorders with limited treatment options.